Loyal
Loyal is a clinical-stage veterinary biopharmaceutical company developing longevity drugs for senior dogs, with lead candidate LOY-002 targeting metabolic dysfunction via a once-daily prescription pill, pursuing FDA Expanded Conditional Approval and a DTC go-to-market model.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2C
- OfferingServices
What Loyal does
Loyal (legal entity: Loyal Animal Health, Inc.) is a clinical-stage veterinary biopharmaceutical company founded in 2019 and headquartered in San Francisco. Its mission is to develop longevity drugs that extend the healthy lifespan of senior dogs, with lead program LOY-002 — a once-daily, beef-flavored prescription pill targeting metabolic dysfunction via IGF-1 hormone reduction, a mechanism designed to mimic the effects of caloric restriction on age-related decline. The drug candidate is intended for dogs aged 10+ and weighing at least 14 lb, and three drug programs are in development across the portfolio. LOY-002 has completed two of the three major FDA technical sections (Reasonable Expectation of Effectiveness and Target Animal Safety) required for Expanded Conditional Approval, with the manufacturing/CMC section still in progress.
The company's clinical evidence base is anchored by the STAY trial — described as the largest clinical trial in veterinary medicine history — with 1,317 dogs enrolled across approximately 70 veterinary clinics. Loyal plans to commercialize LOY-002 through a direct-to-consumer prescription model comparable to Hims & Hers and Ro, complemented by its existing veterinary clinic network for prescription fulfillment and patient monitoring. Pricing has not been disclosed, and the company is pre-revenue pending regulatory clearance. Loyal has raised more than $250 million in total private capital across rounds from 2020 through 2026, most recently a $100 million Series C in February 2026 led by age1 with participation from Baillie Gifford and The Longevity Fund. Customer-facing channels beyond drug distribution include the Loyal Learning Hub, a RACE-approved continuing-education platform for veterinarians, plus content marketing and earned media in major national outlets.
Loyal firmographics
Firmographics- Name
- Loyal
- Legal name
- Loyal Animal Health, Inc.
- Website
- https://loyalfordogs.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Loyal is a clinical-stage veterinary biopharmaceutical company developing longevity drugs for senior dogs, with lead candidate LOY-002 targeting metabolic dysfunction via a once-daily prescription pill, pursuing FDA Expanded Conditional Approval and a DTC go-to-market model.
- Ownership category
- akta.pro rank
Loyal industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Veterinary Services (54194)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Companion Animal Therapeutic Diets (Prescription Diets) (HLAMAHAA)
Keywords
Where Loyal is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Loyal business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Prescription Drug Sales: Loyal plans to generate revenue through sales of its longevity drug LOY-002 as a prescription medication for senior dogs. The company intends to commercialize independently through a direct-to-consumer model similar to Hims & Hers and Ro.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Loyal product offering
Product offeringCore offering
Loyal is developing a portfolio of prescription longevity drugs for senior dogs, with LOY-002 as its lead program. LOY-002 is a once-daily beef-flavored prescription pill designed for dogs age 10 and older (14+ lb) that targets metabolic dysfunction to extend healthy lifespan. The company also offers the Loyal Learning Hub, a free library of RACE-approved continuing education courses for veterinary teams on canine aging.
Product overview
Loyal is developing a portfolio of longevity drugs for dogs, with LOY-002 as the lead program. LOY-002 is a once-daily prescription pill targeting metabolic dysfunction in senior dogs (age 10+). The company also offers the Loyal Learning Hub, a veterinary education platform with RACE-approved CE courses on canine aging. Loyal has 3 drug programs in development and is pursuing FDA Expanded Conditional Approval for LOY-002.
Differentiator
Problem solved
Functional benefit
Products and services
- LOY-002
Quantifiable outcome
- 1,317 dogs enrolled in pivotal STAY clinical trial across approximately 70 veterinary clinics
- +2 more outcomes
Companies that use Loyal
Customer profileSegments2 records
Ideal customer profiles2 records
Loyal technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Loyal partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights6 records
Loyal competitors and assessment
Company assessmentBroad incumbents
- Zoetis: The world's largest pure-play animal health company, offering veterinary pharmaceuticals, vaccines, diagnostics, and parasiticides across companion and livestock animals. Zoetis is comparable as a broad incumbent that could enter or acquire into the canine longevity drug category once Loyal validates the market.
- Elanco Animal Health: Major global animal health company with a broad portfolio of companion animal therapeutics. Elanco is comparable as a broad incumbent competitor and potential fast-follower in canine healthspan / longevity pharmaceuticals.
- IDEXX Laboratories: Leading veterinary diagnostics and reference-lab company expanding into software and practice management. IDEXX is comparable as a deep veterinary-channel incumbent that controls significant touchpoints with U.S. companion animal practices.
- Ceva Santé Animale: Global veterinary pharmaceutical company with a large companion animal portfolio including behavioral and therapeutic products. Comparable as a broad incumbent with the R&D and distribution reach to compete in canine therapeutics.
- Virbac: Independent global animal health company specializing in veterinary pharmaceuticals across companion and production animals. Comparable as a mid-sized incumbent with active companion animal therapeutic franchises.
- Phibro Animal Health: Diversified animal health and nutrition company with companion animal and livestock pharmaceutical lines. Comparable as a broad incumbent operating in the veterinary therapeutics market.
Direct peers
- Hims & Hers Health: Public telehealth and direct-to-consumer prescription drug company cited by Loyal as the model for its LOY-002 distribution. Comparable on go-to-market mechanics (DTC prescription acquisition and fulfillment), not on therapeutic area.
- Ro: Direct-to-consumer telehealth and prescription pharmacy company that has built its own vertically integrated compounding and fulfillment capabilities. Comparable to Loyal's stated DTC commercialization blueprint for LOY-002.
Emerging players
- Modern Animal: Membership-based veterinary clinic chain with a digitally enabled, consumer-grade experience. Comparable as an emerging player shaping how pet owners access prescription veterinary care, a channel Loyal plans to leverage.
- Dog Aging Project: Large longitudinal research initiative studying aging in companion dogs, including the rapamycin-based TRIAD trial. Comparable as the leading academic longevity-in-dogs effort and a potential scientific collaborator or competitor for evidence generation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Loyal social profiles
Digital presenceLoyal financial estimates
Financial estimateRevenue estimate
Valuation estimate
Loyal leadership team
Management profileNumber of profiles
Profiles4 records
Loyal funding detail
Funding detailFunding overview
Funding rounds9 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Loyal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Loyal
What does Loyal do?
Loyal is developing a portfolio of prescription longevity drugs for senior dogs, with LOY-002 as its lead program. LOY-002 is a once-daily beef-flavored prescription pill designed for dogs age 10 and older (14+ lb) that targets metabolic dysfunction to extend healthy lifespan. The company also offers the Loyal Learning Hub, a free library of RACE-approved continuing education courses for veterinary teams on canine aging.
Is Loyal a public or private company?
Loyal is a private company. It is classified as venture growth investor backed and is currently operating.
When was Loyal founded?
Loyal was founded in 2019. It employs 101 to 250 people.
Where is Loyal based?
Loyal is headquartered in San Francisco, United States, in the North America region.
How does Loyal make money?
One revenue line is on record: prescription Drug Sales.
Who are Loyal's main competitors?
Broad incumbents on record are Zoetis, Elanco Animal Health, IDEXX Laboratories, Ceva Santé Animale, Virbac and Phibro Animal Health. Direct peers are Hims & Hers Health and Ro. Emerging players are Modern Animal and Dog Aging Project.
Does Loyal have an API?
No public API is recorded for Loyal.
What industry is Loyal in?
Loyal's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAHAA, Companion Animal Therapeutic Diets (Prescription Diets). Its NAICS code is 54194 and its SIC code is 2834.